Company intelligence / Profile preview
Heber Biotec
Playa, La Habana, Cuba
- Ownership
- Private
- Development stage
- Other
01
Overview
Heber Biotec S.A. has several products approved and commercialized, including biosimilars, prophylactic vaccines, and biologics for infectious and chronic disease indications. Notable products are marketed worldwide, including recombinant interferons and vaccines. Clinical results for these products demonstrate effectiveness in several therapeutic areas, such as 83.9% granulation tissue coverage and 46.2% lesion closure for Heberprot-P in diabetic foot ulcers.
- Therapeutic areas
- EndocrinologyInfectious DiseasesGastroenterologyPulmonologyOncology
- Modalities
- VaccineBiologicRecombinant proteinBiosimilarSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Heber Biotec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heber Biotec.